意大利人群脊髓灰质炎病毒中和抗体阳性率:系统综述与Meta分析
该研究系统检索2012年1月1日至2022年11月15日发表的文献,纳入7项研究,评估意大利人群抗脊髓灰质炎病毒中和抗体阳性率。合并结果显示无PV1、PV2、PV3中和抗体的受试者比例分别为6.4%(95%CI=0.5-16.9)、5.3%(95%CI=0.4-14.2)和13.0%(95%CI=4.0-25.7;I²=98.5%)。作者结论认为公共卫生机构应意识到无脊灰国家野毒株再输入的风险,需保持人群高免疫水平并加强主动监测。
要点
- 意大利人群无PV1中和抗体的合并比例为6.4%(95%CI=0.5-16.9)。
- 无PV2中和抗体的合并比例为5.3%(95%CI=0.4-14.2),无PV3为13.0%(95%CI=4.0-25.7;I²=98.5%)。
- 中和抗体水平随年龄增长而下降,反映末次接种疫苗后的时间这一真实风险因素。
核心结论
- 公共卫生机构必须意识到无脊灰国家野PV再输入的风险,需保持人群高免疫水平并加强主动监测系统。
研究设计与样本
- 系统综述与Meta分析,检索MEDLINE/PubMed、ISI Web of Knowledge和Scopus,纳入2012年1月1日至2022年11月15日发表的7项研究。
- 研究目的是评估意大利人群抗PV中和抗体阳性率。
主要发现
- 无PV1中和抗体的合并比例为6.4%(95%CI=0.5-16.9)。
- 无PV2中和抗体的合并比例为5.3%(95%CI=0.4-14.2)。
- 无PV3中和抗体的合并比例为13.0%(95%CI=4.0-25.7;I²=98.5%)。
- 中和抗体水平似乎随年龄增长而下降,该下降是末次疫苗剂量后时间这一真实风险因素的替代指标。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The introduction of anti-poliomyelitis vaccines has driven progress toward the global eradication of wild polioviruses, a millennium goal of the World Health Organization. With the vaccination campaigns carried out since 1964, in 2002 Italy was certified polio-free, considering that no cases had been recorded since 1983. Nevertheless, it is crucial to guarantee high level of immunization coverage also in low-endemicity countries, considering that sporadic polio cases can be recorded. To evaluate the presence of susceptible subjects in the population, seroepidemiological studies are key actions. METHODS: We conducted a systematic review of the relevant literature to evaluate the prevalence of anti-PV neutralizing antibodies in Italian population. Seven studies, selected among scientific articles available in MEDLINE/PubMed, ISI Web of Knowledge and Scopus and published from January 1, 2012, to November 15, 2022, were included. RESULTS: The pooled prevalence of subjects without PV1 neutralizing antibodies was 6.4% (95%CI = 0.5-16.9), for PV2 it was 5.3% (95%CI = 0.4-14.2), and for PV3 it was 13.0% (95%CI = 4.0-25.7; I2 = 98.5%). Levels of neutralizing antibodies appears to decrease with increasing age; this decline is a proxy for the real risk factor, which is the time since the last vaccine dose. CONCLUSIONS: Public health institutions must be aware of the risk of reintroduction of wild PV in polio-free countries and therefore they must keep high level of immunization in population and reinforce the active surveillance systems.
引用
- Tafuri S, Cuscianna E, Bianchi FP, et al. Prevalence of poliovirus neutralizing antibodies in Italian population: A systematic review and meta-analysis. Vaccine. 2023. PMID: 37121798. doi:10.1016/j.vaccine.2023.04.047
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。